Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jarushka Naidoo MD

Jarushka Naidoo MD

Assistant Professor of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland

Dr. Naidoo is an Assistant Professor of Oncology and attending physician at the Sidney Kimmel Cancer Center at Johns Hopkins University, specializing in the field of lung cancer and immunotherapy. 

Dr. Naidoo obtained her medical degree from Trinity College in Dublin, Ireland, and is originally from Durban in South Africa. She completed her internal medicine and medical oncology training in Ireland, followed by an advanced medical oncology fellowship at Memorial Sloan Kettering Cancer Center in New York, prior to joining the faculty at Johns Hopkins. Dr. Naidoo is the recipient of multiple awards including an NIH KL2 scholar award, ASCO merit award, and young investigator award for non-small cell lung cancer. 

Dr. Naidoo’s research interest is in clinical trials of combinations of immunotherapies for the treatment of lung cancer and other thoracic cancers, as well as the side effects of immunotherapies for cancer, why these happen, and how they can be best managed. She serves on US national guidelines (NCCN, SITC) for the management of immune-related toxicity. She is also the chair of the immunotherapy subcommittee of the NRG cooperative group, as well as Co-chair of the Johns Hopkins multidisciplinary immune-related toxicity team.

Recent Contributions to PracticeUpdate:

  1. 2015 PracticeChangers in Oncology: FDA-Approved EGFR TKIs for Acquired Resistance to Targeted Therapy in Lung Cancer
  2. Pneumonitis in Patients Receiving Anti-PD-1/PD-L1 Therapy
  3. At What Point Does Cancer Treatment Cost Too Much? Part 2
  4. At What Point Does Cancer Treatment Cost Too Much? Part 1
  5. ASCO 2015 Recap: Dr. Bradley Somer on RCC—Part 1
  6. ASCO 2015 Recap: Dr. Bradley Somer on RCC—Part 2
  7. ASCO 2015 Recap: Dr. Kimberly Blackwell Circles Back to HER2/ER Breast Cancer—Part 1
  8. ASCO 2015 Recap: Dr. Kimberly Blackwell Circles Back to HER2/ER Breast Cancer—Part 2
  9. ASCO 2015 Recap: Breast Cancer, Metastasis, and Prophylactic Mastectomy—Part 1
  10. ASCO 2015 Recap: Breast Cancer, Metastasis, and Prophylactic Mastectomy—Part 2

Most Read This Week

Recently Updated